A Phase Ib/II Trial of Capeox Regimen Combined With Sintilimab and Bevacizumab in First-line Treatment for Recurrent or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 18 May 2023
At a glance
- Drugs Bevacizumab (Primary) ; Sintilimab (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 12 May 2023 Status changed from not yet recruiting to recruiting.
- 09 Dec 2022 New trial record